<DOC>
	<DOCNO>NCT02618629</DOCNO>
	<brief_summary>The aim Phase I study determine absorption , metabolism , excretion 14C-Z-215 healthy male subject follow single oral administration therapeutically relevant dose level ( 20 mg ) .</brief_summary>
	<brief_title>Mass Balance Metabolism Study 14C-Z-215</brief_title>
	<detailed_description />
	<criteria>Any race/ethnic origin Subjects body mass index ( BMI ) 18.5 30.0 kg/m2 Subjects body weight 50 110 kg Subjects give write informed consent participate study , abide study restriction . Subjects significant history drug allergy , determine Investigator . Subjects serum hepatitis carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody . Subjects positive result test human immunodeficiency virus ( HIV ) antibody . Subjects expose radiation result occupation . Subjects , opinion Investigator , participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>